FINAL RESULTS AND PHARMACOECONOMIC ANALYSIS OF A TRIAL COMPARING TWO NEOADJUVANT CHEMOTHERAPY (CT) REGIMENS FOLLOWED BY SURGERY IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II RANDOMISED STUDY BY THE EUROPEAN LUNG CANCER WORKING PARTY

被引：0
|
作者：
Berghmans, Thierry
Lafitte, Jean-Jacques [1 ]
Giner, Vicente
Berchier, Marie-Claude
Scherpereel, Arnaud [1 ]
Lewin, Daniel
Paesmans, Marianne
Meert, Anne-Pascale
Bosschaerts, Thierry [2 ]
Leclercq, Nathalie
Sculier, Jean-Paul
机构：
[1] CHRU Lille, Lille, France
[2] Hop St Pierre, St Pierre, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Non small cell lung carcinoma; Surgery; neoadjuvant chemotherapy; Cost-effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S465 / S466
页数：2
相关论文
共 50 条
  • [1] Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomised study by the European Lung Cancer Working Party
    Berghmans, T.
    Lafitte, J. J.
    Giner, V.
    Berchier, M. C.
    Scherpereel, A.
    Lewin, D.
    Paesmans, M.
    Meert, A. P.
    Bosschaerts, T.
    Leclercq, N.
    Sculier, J. P.
    LUNG CANCER, 2012, 77 (03) : 605 - 610
  • [2] Final results of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomized study by the European Lung Cancer Working Party
    Berghmans, T.
    Lafitte, J.
    Giner, V.
    Berchier, M.
    Scherpereel, A.
    Paesmans, M.
    Meert, A.
    Bosschaerts, T.
    Leclercq, N.
    Sculier, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Results of the IFCT 0002 phase III study comparing a preoperative and a perioperative chemotherapy (CT) with two different CT regimens in resectable non-small cell lung cancer (NSCLC)
    Westeel, V.
    Milleron, B.
    Quoix, E.
    Breton, J. L.
    Braun, D.
    Puyraveau, M.
    Bigay-Game, L.
    Pujol, J. L.
    Morin, F.
    Depierre, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
    Besse, B.
    Adam, J.
    Cozic, N.
    Chaput-Gras, N.
    Planchard, D.
    Mezquita, L.
    Remon Masip, J.
    Lavaud, P.
    Naltet, C.
    Gazzah, A.
    de Montpreville, V. Thomas
    Ghigna, M. -R.
    Mussot, S.
    Fadel, E.
    Mabille, L.
    Duchemann, B.
    Barlesi, F.
    Soria, J-C.
    Caramella, C.
    Mercier, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S794 - S795
  • [5] Phase III study comparing preoperative and perioperative chemotherapy (CT) with two different regimens in resectable non-small cell lung cancer (NSCLC): the results of the IFCT-0002 study
    Quoix, Elisabeth
    Lavole, Armelle
    Westeel, Virginie
    Puyraveau, Marc
    Bigay-Game, Laurence
    Ozenne, Gervais
    Gervais, Radj
    Lebeau, Bernard
    Debieuvre, Didier
    Poudenx, Michel
    David, Philippe
    Morin, Franck
    Cadranel, Jacques
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S330 - S331
  • [6] Phase II study of Neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer
    Ramnath, N
    Sommers, E
    Robinson, L
    Nwogu, C
    Sharma, A
    Cantor, A
    Bepler, G
    CHEST, 2005, 128 (05) : 3467 - 3474
  • [7] Neoadjuvant atezolizumab plus chemotherapy in resectable non-small cell lung cancer (NSCLC).
    Shu, Catherine A.
    Grigg, Claud
    Chiuzan, Codruta
    Garofano, Robert F.
    Patel, Vijeta
    Hernandez, Susana
    Negri, Tiffany
    Sacher, Adrian G.
    Smith-Marrone, Stephanie
    Stoopler, Mark
    Gainor, Justin F.
    Awad, Mark M.
    D'Ovidio, Frank
    Sonett, Joshua R.
    Bacchetta, Matthew
    Saqi, Anjali
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small-cell lung cancer (NSCLC).
    Ramnath, N
    Sommers, E
    Robinson, L
    Nwogu, C
    Tan, D
    Sharma, A
    Cantor, A
    Lawrence, D
    Simon, G
    Bepler, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 689S - 689S
  • [9] A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
    Owen, Dwight Hall
    Bunn, Paul A.
    Johnson, Bruce E.
    Kwiatkowski, David J.
    Kris, Mark G.
    Wistuba, Ignacio Ivan
    Gandhi, Mayank
    Phan, See
    Shames, David S.
    Schulze, Katja
    Yu, Wei
    Aisner, Dara
    Chaft, Jamie E.
    Garon, Edward B.
    Lee, Jay M.
    Minna, John D.
    Rusch, Valerie W.
    Reckamp, Karen L.
    Wozniak, Antoinette J.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer.
    Westeel, V.
    Milleron, B. J.
    Quoix, E. A.
    Puyraveau, M.
    Moro-Sibilot, D.
    Braun, D.
    Lebeau, B.
    Lemarie, E.
    Debleuvre, D.
    Deplerre, A. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345